I-HP518 itholwe futhi yathuthukiswa inkundla yokutholwa kwezidakamizwa ezihlosiwe ka-Hinova zokucekela phansi amaprotheni. Inamandla okunqoba ukumelana nemithi yomdlavuza wendlala yesinye ngenxa yokuguqulwa okuthile kwe-AR.
I-Chimeric degraders ama-molecule amancane asebenza kabili akhuthaza ukuwohloka kwamaprotheni okuhlosiwe anamandla aphezulu kanye nokukhetha okuphezulu. Lobu buchwepheshe bunamandla okukhomba okuqondiwe okungadakwa futhi bunqobe inkinga yokumelana nezidakamizwa yemithi yendabuko yama-molecule amancane.
"Lesi yingqopha-mlando ebalulekile ekuqhubekeleni phambili kwemizamo yethu kusukela ekutholakaleni kwezidakamizwa kuya ocwaningweni lomtholampilo," kusho u-Yuanwei Chen, Ph.D., uMongameli kanye ne-CEO ye-Hinova. "Sijabule ngakho futhi sizinikele ekuletheni izindlela ezintsha zokwelapha ezigulini emhlabeni wonke!"
Ngenkundla yokutholwa kwezidakamizwa ezihlosiwe zokonakaliswa kwamaprotheni, i-Hinova ingakwazi ukuhlola umsebenzi wokuwohloka kwamaprotheni ngokushesha futhi ifeze ukuklama okuphumelelayo kanye nokwenza ngokugcwele okonakaliswa kwe-chimeric. Ngaphezu kwalokho, u-Hinova unolwazi olujulile ekulawuleni ukukhiqizwa kwamakhemikhali kwe-Chimeric degrader compounds.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- Through the targeted protein degradation drug discovery platform, Hinova can screen protein degradation activity rapidly and accomplish efficient design and optimization of chimeric degraders.
- “This is a significant milestone in the progress of our efforts from drug discovery to the clinical study,”.
- This technology has the potential to target non-druggable targets and to overcome the drug resistance issue of traditional small molecule drugs.
